SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?


To: Robert K. who wrote (7560)10/28/1998 6:59:00 PM
From: Cacaito  Read Replies (1) | Respond to of 17367
 
52 with 14 deaths in the Amsterdam study vs 25 and 1 death in Xoma's phase II with BPI. This is a very striking difference. Both groups received top start of the art care.

The inflammatory mediators measure are in many respects the same in Xoma's phase II with correlation to severity of disease.

Phase III will hopefully show the same findings.